Clinical trial
A Phase I, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma
NCT01223209 is registered in ClinicalTrials.gov with Lytix Biopharma AS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma
- Lead sponsor
- Lytix Biopharma AS
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2010
- Completion date
- January 31, 2012
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.